You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
Hot medicines: stability of protein-based medicines
Developing countries are for a large part dependent on western countries for their medicines. A large part of those medicines contain therapeutic proteins that are sensitive to tropical conditions which decrease or completely nullify their effectiveness.
The constant cooling during transport, however, is rather expensive and not always a possibility. This project aims to develop ways to stabilize the proteins in these medicines under tropical conditions without a significant increase in development costs. The focus of this project is on the World Health Organization priority medicines: oxytocin and insulin as well as vaccines for influenza. So far a major breakthrough has been achieved for oxytocin which can now be kept stabile at forty degrees Celsius. For influenza a stabilizing factor has been found as well, possibly leading to a new stabile formulation.
Full project title: Hot medicines: breaking the cold chain requirement for polypeptide-based priority medicines
Start date: December 2006
End date: February 2012
Goal: Develop drug formulations that are stable under tropical conditions
Principal investigator: Wouter Hinrichs
Project size: 2,3 FTE's
Partners: Abbott, MSD, Leiden University, OctoPlus NV, University of Groningen
Vinay Saluja (project D6-202)
Novel Perspectives for Influenza Vaccine Formulation and Administration
“Running public-private partnerships is a profession by itself. TI Pharma is an excellent example of how you can do this in an effective way.”
Director/Secretary of the Medicines Evaluation Board